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Abstract
Endothelial cells in solid tumors play an important role in tumor growth, invasion and metastasis through angiogenesis.
We have recently cloned two tumor vascular antigens from isolated rat tumor vascular endothelial cells (TEC). One is CD44,
a family of cell surface proteins implicated in adhesion interactions and tumor metastasis. The other is OTS-8, a marker for
osteoblast into osteocyte transition and type I alveolar epithelial cells termed as E11 antigen and RTI40, respectively. To test
for a possible interaction between the two antigens on endothelial cells in tumor angiogenesis, we examined in vivo
association of CD44 with OTS-8 using lysates of isolated rat TEC and COS-7 cells cotransfected with CD44 and OTS-8
expression plasmids. The association was detected by direct co-immunoprecipitation of the two types of cells lysed with
digitonin, whereas the detection was lost when lysed with Nonidet P-40. To confirm this association, intact COS-7 cells
cotransfected were reacted with homobifunctional N-hydroxysuccinimide ester crosslinking reagents. Immunoblot analysis
showed a crosslinked CD44/OTS-8 protein complex of 120 kDa, suggesting the proximity of the two proteins. These findings
provide evidence of a weak physical association between CD44 and OTS-8 in TEC, and suggest that OTS-8 may alter the
mode of endothelial cell growth and/or migration induced by CD44 in tumor angiogenesis. ß 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Tumor angiogenesis, i.e. formation of new blood
vessels, enhances tumor growth, invasion and meta-
stasis [1]. Tumor vascular endothelial cells (TEC) are
a major component of the tumor vasculature. It is
therefore important to elucidate the nature of TEC
for a full understanding of tumor angiogenesis and
ultimately to design new therapeutic approaches to
eradicate tumors. Only a few studies have so far been
reported on TEC probably due to di⁄culties in iso-
lation of these cells from solid tumor tissues. We
previously established a method for the isolation
for rat TEC and identi¢ed 80 and 40 kDa antigens
on the cell surface [2]. cDNAs encoding the antigens
were separately cloned from a cDNA library pre-
pared from rat TEC. The cDNA sequences were ho-
mologous to CD44 and OTS-8 sequences [3]. CD44
is a family of cell surface proteins implicated in cell
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migration, lymphocyte activation and tumor progres-
sion [4]. Although CD44 is widely distributed in
many tissues and cell types, there are only a few
studies that have examined its expression on endo-
thelial cells (EC). Trochon et al. [5] reported that a
monoclonal antibody (mAb) against CD44 abolished
the stimulating e¡ect of hyaluronan, one of the nat-
ural ligands of CD44, on EC migration and prolifer-
ation. Gri⁄oen et al. [6] described a speci¢c expres-
sion of CD44 on activated EC by angiogenic factors
and EC isolated from the vasculature of human solid
tumors. Thus, the enhanced expression of CD44 on
TEC may be involved in growth and locomotion of
these cells as well as tumor cells. On the other hand,
a few laboratories have investigated OTS-8. Nose et
al. [7] identi¢ed three target genes for the early re-
sponse gene products produced by phorbol esters in
murine osteoblastic line MC3T3-E1 cells. It was
shown that, of these genes, OTS-8 was a novel one
and its mRNA was detected almost exclusively in the
lungs. Recently, direct amino acid sequencing of pu-
ri¢ed rat RTI40, a biochemical marker of apical plas-
ma membrane of rat alveolar type I cells, showed
homology to murine OTS-8 [8]. Furthermore, Wet-
terwald et al. [9] identi¢ed rat E11 antigen as a
marker for mature osteoblasts and newly formed os-
teocytes. They found homology in cDNA sequence
between rat E11 antigen and murine OTS-8. Further-
more, studies from our laboratories con¢rmed that
amino acid sequences of rat RTI40 and cDNA se-
quence of rat E11 antigen were similar to those of rat
40 kDa antigen expressed on TEC [3].
The purpose of the present study was to examine
the association between CD44 and OTS-8 on EC in
tumor angiogenesis. We conducted a direct co-immu-
noprecipitation using lysates of isolated rat TEC and
COS-7 cells cotransfected with CD44 and OTS-8 ex-
pression vectors, and crosslinking of the two protein
on COS-7 cells with homobifunctional N-hydroxy-
succinimide ester (NHS-ester) reagents [10].
2. Materials and methods
2.1. Plasmids
cDNAs of both rat CD44 and OTS-8 were cloned
from V gt 11 cDNA library prepared from rat TEC
[3], and inserted into pcDL-SR296 expression vector
[11].
2.2. Antibodies
TES series murine mAbs were generated by fusion
between myeloma cells (P3X63Ag8U.1) and mouse
splenocytes immunized with vesicles of rat TEC [2].
TES-27 and TES-17 mAbs recognize rat CD44 and
rat OTS-8, respectively, expressed on COS-7 cells
transfected with the plasmids [3]. mAbs were puri¢ed
from ascites £uid samples by protein A (Biosepra,
Locke Drive, MA, USA) chromatography. Anti-rat
CD44 antibody (OX-49 clone) was purchased from
PharMingen (San Diego, CA, USA). MOPC-31C
(ATCC CCL 130) was used as control mAb.
2.3. Crosslinking reagents
Homobifunctional NHS-ester crosslinking re-
agents [10], DSS (disuccinimidyl suberate), BS3 (bis-
(sulfosuccinimidyl)suberate) water-soluble analog of
DSS and DSG (disuccinimidyl glutarate), were pur-
chased from Pierce (Rockford, IL, USA). Water-in-
soluble NHS-ester crosslinkers, DSS and DSG, were
dissolved in dry DMSO at 20 mM, while water-solu-
ble NHS-ester crosslinker, BS3, was dissolved in
water at the same concentration. All reagents were
prepared just prior to use.
2.4. Cells
Rat KMT-17 ¢brosarcoma cells [12], induced by
3-methylcholanthrene in WKA rats, were maintained
in ascites or in solid form grown subcutaneously in
WKAH/Hkm rats (Japan SLC, Shizuoka, Japan).
TEC were isolated from solid KMT-17 ¢brosarcoma
as described previously [13] and cultured in Dulbec-
co’s modi¢ed Eagle medium (Gibco, Grand Island,
NY, USA) containing 10% fetal bovine serum (Gib-
co) and 50 Wg/ml EC growth supplement (ECGS,
Becton Dickinson, Bedford, MA, USA).
COS-7 cells (ATCC CRL 1651), maintained in
RPMI 1640 with 10% fetal calf serum (FCS), were
plated at 8U104 cells/ml into 60 mm tissue culture
dishes with 5 ml of RPMI 1640 supplemented with
10% FCS and cultured overnight. After removal of
the culture medium, 2 ml of serum-free RPMI 1640
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containing 10 Wg of CD44 and OTS-8 expression
plasmids and 10 Wl of LipofectAMINE (Gibco
BRL) were added to COS-7 cells and incubated for
6 h at 37‡C in a CO2 incubator. After 6 h trans-
fection, COS-7 cells were cultured for 72 h in fresh
RPMI 1640 with 10% FCS.
2.5. Preparation of cell lysates
Cultured cells were washed with phosphate-bu¡-
ered saline (PBS), then lysed with 50 mM Tris^HCl
bu¡er, pH 7.5, containing 1% digitonin or Nonidet
P-40 (NP-40), 1 mM EDTA, 1 mM PMSF, 150 mM
NaCl and one protease inhibitor tablet (Boehringer
Mannheim, Mannheim, Germany)/50 ml, and incu-
bated for 30 min on ice. After incubation, cell lysates
were centrifuged at 10 000Ug for 15 min at 4‡C, and
the resulting supernatants were subjected to immu-
noprecipitation and immunoblot analysis.
2.6. Immunoprecipitation and immunoblot
Supernatants were incubated overnight at 4‡C with
CNBr-activated Sepharose 4B (Pharmacia Biotech,
Uppsala, Sweden) conjugated with various antibod-
ies. After incubation, immunoprecipitates were
washed ¢ve times with 50 mM Tris^HCl bu¡er (pH
7.5) containing 1% digitonin or NP-40, 1 mM
EDTA, 1 mM PMSF, 500 mM NaCl and one pro-
tease inhibitor tablet/50 ml, and resuspended in so-
dium dodecyl sulfate (SDS) sample bu¡er. After boil-
ing for 3 min, SDS^PAGE was performed under
unreduced conditions, using 4^20% gradient mini
gels (Tefco, Tokyo, Japan). Following electrophore-
sis, proteins on the gels were transferred electrophor-
etically to PVDF membrane (Millipore). After block-
ing non-speci¢c protein binding with 3% skim milk
in TBS-T (25 mM Tris^HCl bu¡er, pH 7.4, 150 mM
NaCl, 3 mM KCl and 0.05% Tween-20), the mem-
brane was treated with the primary antibody diluted
to 10 Wg/ml with TBS-T containing 10% FCS for 1 h
at room temperature. This was followed by incuba-
tion with horseradish peroxidase-conjugated anti-
mouse IgG antibody (Zymed Laboratories, Inc.,
San Francisco, CA, USA) diluted 1000-fold with
TBS-T containing 10% FCS. Detection was per-
formed with enhanced chemiluminescence (Amer-
sham Life Science, Buckinghamshire, UK).
2.7. Crosslinking of CD44 and OTS-8
COS-7 cells were transfected with 10 Wg of CD44
and OTS-8 expression plasmids mixed with 10 Wl of
LipofectAMINE (Gibco BRL) as described above
under Section 2.4. For crosslinking of intact cotrans-
fected COS-7 cells, DSS, BS3 or DSG from a freshly
prepared stock solution was added to the cells in 20
mM sodium phosphate bu¡er, 0.15 M NaCl, pH 7.5
(PBS), at a ¢nal concentration of 1 mM, and the
sample was incubated for 30 min at 24‡C. At the
end of the reaction time, the reaction was quenched
by adding 1 M Tris, pH 7.5, to a ¢nal concentration
of 20 mM, and the reaction mixture was incubated
for an additional 30 min. The treated cells were
washed with PBS three times, then lysed with 50
mM Tris^HCl bu¡er, pH 7.5, containing 1% NP-
40, 1 mM EDTA, 1 mM PMSF, 150 mM NaCl
and one protease inhibitor tablet (Boehringer Mann-
heim)/50 ml, and incubated for 45 min on ice. After
incubation, cell lysates were centrifuged at 10 000Ug
for 15 min at 4‡C, and the resultant supernatants
were subjected to immunoblot analysis as described
above under Section 2.6, using TES-17, TES-27 or
control mAb (MOPC-31C) as the primary antibody.
3. Results
3.1. Association between CD44 and OTS-8 expressed
on rat TEC
The association between CD44 and OTS-8 was
detected by direct co-immunoprecipitation in lysates
of rat TEC isolated from solid tumors (Fig. 1). Im-
munoprecipitation of lysates of rat TEC with TES-27
antibody against CD44 (lane 4) yielded a protein that
was also detected with TES-17 antibody against
OTS-8 (lane 2). Furthermore, immunoprecipitation
of rat TEC lysates with TES-17 antibody to OTS-8
(lane 1) produced a protein that was also recognized
with TES-27 antibody to CD44 (lane 3).
3.2. Association between CD44 and OTS-8
cotransfected in COS-7 cells
The association between CD44 and OTS-8 was
detected by direct co-immunoprecipitation in lysates
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of COS-7 cells cotransfected with CD44 and OTS-8
expression plasmids (Fig. 2). As shown in Fig. 2A
(lanes 1 and 7), CD44 was noted in OTS-8 immune
complexes precipitated by TES-17 antibody. In addi-
tion, OTS-8 was detected in CD44 immune com-
plexes precipitated by TES-27 antibody (Fig. 2A,
lanes 2 and 8). Immunoprecipitation of lysates with
MOPC-31C control antibody produced a protein
that was not recognized with TES-17 or TES-27 anti-
body (Fig. 2A, lanes 3 and 9). Anti-CD44 antibody
(OX-49) could detect immunoprecipitates not only
by TES-27 (Fig. 2B, lane 2), but also by TES-17
(Fig. 2B, lane 1). However, no immunoprecipitates
were detected when COS-7 cells were lysed with NP-
40 (Fig. 2A, lanes 5 and 10).
3.3. Crosslinking of CD44 and OTS-8 cotransfected
in COS-7 cells
To con¢rm the detected association between CD44
and OTS-8 by direct co-immunoprecipitation in ly-
sates of COS-7 cells cotransfected with CD44 and
OTS-8 expression plasmids, the cotransfected COS-
7 cells were reacted with DSS, a homobifunctional
NHS-ester crosslinking reagent. Immunoblot analy-
sis by TES-17 showed that a crosslinked CD44 (80
kDa)/OTS-8 (40 kDa) complex was evident as a 120
kDa protein (Fig. 3, lane 1). A 120 kDa protein
formation was also observed by treatment with
BS3, a water-soluble analog of DSS, which does
Fig. 2. Co-immunoprecipitation of CD44 and OTS-8 in COS-7 cells cotransfected with CD44 and OTS-8 expression plasmids. Cells
were lysed with digitonin (A, lanes 1^3, 7^9; B, lanes 1^3) or NP-40 (A, lanes 4^6, 10^12) and subjected to immunoprecipitation (IP)
followed by immunoblot (Blot) analysis with the indicated antibody. TES-17 and TES-27 antibodies recognize rat OTS-8 and rat
CD44, respectively. OX-49 antibody (PharMingen) reacts with rat CD44. MOPC was used as control IgG.
Fig. 1. Co-immunoprecipitation of CD44 and OTS-8 in TEC
isolated from rat solid KMT-17 tumors. Cells were lysed with
digitonin and subjected to immunoprecipitation (IP) followed
by immunoblot (Blot) analysis with the indicated antibody.
TES-17 and TES-27 antibodies recognize rat OTS-8 and rat
CD44, respectively.
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not permeate the membrane (Fig. 3, lane 2). On the
other hand, DSG, a crosslinking reagent with shorter
spacer arm length (7.72 Aî ) than DSS and BS3 (11.4
Aî ), failed to form the 120 kDa protein complex (Fig.
3, lane 3). TES-27 as well as control mAb (MOPC-
31C) did not detect the CD44/OTS-8 complex by
immunoblot analysis (data not shown).
4. Discussion
The experiments presented here provide new ¢nd-
ings of the physical association of CD44 with OTS-8
on two types of cells: rat TEC isolated from solid
tumors and COS-7 cells cotransfected with CD44
and OTS-8 expression vectors. Using digitonin ly-
sates of the rat TEC, we detected the in vivo associ-
ation between the two endogenous molecules by di-
rect co-immunoprecipitation. Moreover, in COS-7
cells cotransfected with vectors that express CD44
and OTS-8, the association was also observed when
cells were lysed with digitonin. However, treatment
of COS-7 lysates with NP-40 often induced loss of
detection, indicating that CD44 may associate
weakly with OTS-8. To con¢rm this association,
COS-7 cells cotransfected with CD44 and OTS-8 ex-
pression plasmids were reacted with homobifunction-
al NHS-ester crosslinking reagents [10]. Immunoblot
analysis by TES-17 showed a 120 kDa crosslinked
CD44/OTS-8 protein complex using DSS or its
water-soluble analog BS3, which does not permeate
the membrane, suggesting proximity of the two pro-
teins, at least on the cell surface. Loss of detection of
the crosslinked protein by TES-27 may be due to
conformational changes in the epitope region of
CD44 molecule, when NHS-ester crosslinkers reacted
with primary amines on the N-termini or O-amine of
lysine of CD44.
We previously found OTS-8 expression on TEC
[3], however, its functional role has not yet been
determined. RTI40, homologous to mouse OTS-8,
is known as a biochemical marker of type I alveolar
epithelial cells, which are indispensable for gas ex-
change and regulation of lung £uid [14]. This marker
is also expressed in the choroid plexus and eye ciliary
epithelium, suggesting that this molecule functions as
a hypothetical ion transport or osmoregulator [8].
However, the expression of mouse, rat and human
T1 K, homologous to OTS-8, in Xenopus oocytes did
not increase osmotic water permeability, suggesting
that OTS-8 is not involved in the high trans-alveolar
water permeability in the intact lung [15]. Transport-
ers like Na/H and Cl3/HCO33 exchangers also
play a role in the regulation of cell volume and cy-
tosolic pH in osteoblasts that express rat E11 antigen
whose cDNA sequence shows homology to mouse
OTS-8 [16]. It is well known that vascular endothelial
growth factor secreted by tumor cells confers high
permeability phenotype on TEC, suggesting that
OTS-8 on TEC may be implicated, in part, in acqui-
sition of the enhanced permeability. In addition,
both cytoplasmic processes of osteocytes and apical
surface of type I alveolar epithelial cells were stained
by mAb for E11 antigen [9], suggesting that OTS-8
may contribute to cell movement. This notion is sup-
ported by our previous ¢ndings that OTS-8 is present
in sprouting TEC, but not tubular endothelium, as
demonstrated by immunohistochemical analysis of
tumor specimens [3]. Furthermore, OTS-8 gene was
originally found as a member of the secondary re-
sponse group, which may be controlled by tran-
scription factors induced by tumor-promoting
phorbol esters, and thus OTS-8 mRNA was induced
by 12-O-tetradecanoylphorbol-13-acetate, epidermal
Fig. 3. Crosslinking of CD44 and OTS-8 in COS-7 cells co-
transfected with CD44 and OTS-8 expression plasmids. The co-
transfected COS-7 cells were reacted with homobifunctional
NHS-ester crosslinking reagents, DSS (lane 1), its water-soluble
analog BS3 (lane 2) or DSG (lane 3), and subjected to immuno-
blot (Blot) analysis with TES-17 antibody which recognizes rat
OTS-8.
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growth factor or cell transformation with v-ras onco-
gene [7]. Although TEC are de¢ned as non-trans-
formed cells, we postulate that OTS-8 may play a
role in cell transformation when surrounded by tu-
mor cells.
TES-23 was used for anti-CD44 antibody in pre-
vious studies reported by our group [3]. However, in
a series of preliminary experiments, it was found to
be less reactive against denatured protein by NP-40
or digitonin for immunoprecipitation as well as by
SDS for Western blotting. Accordingly, we used
TES-27, an alternative anti-CD44 antibody, in the
present experiments. We con¢rmed that TES-27
could recognize denatured CD44, and that TES-27,
as well as commercially available anti-CD44 anti-
body, could totally inhibit the speci¢c binding of
FITC-labeled TES-23 to tumor-derived EC in both
FACS [3] and cell enzyme-linked immunosorbent as-
say system. In addition, TES-27 as well as TES-23
could recognize recombinant CD44 expressed on
COS-7 cells [3]. Therefore, there are no di¡erences
in these antibodies with regard to reactivity against
intact or glutaraldehyde-¢xed antigen.
The pathophysiological signi¢cance of CD44^
OTS-8 association on vascular EC in solid tumors
is still unclear. CD44 serves as a binding site for a
variety of molecules such as extracellular matrix
components [17], cytoskeletal proteins [17], growth
factors [18] and matrix metalloproteinase [19]. The
important point to note is that, unlike these mole-
cules, OTS-8 is a transmembrane protein [7] with
possible physiological functions, since sequence anal-
ysis of RTI40 revealed cAMP- and protein kinase C-
dependent phosphorylation sites [20]. In osteoblasts
and osteocytes, CD44 is localized in cytoplasmic pro-
cesses and may be an important membrane-bound
glycoprotein linking extracellular matrix and cyto-
skeleton [21]. OTS-8 is also localized in cytoplasmic
processes of osteocytes by staining with mAb for E11
antigen [9]. Since the binding of extracellular matrix
through CD44 is involved in cell motility [22], it is
possible that the association of OTS-8 may alter the
mode of EC movement induced by CD44 in tumor
angiogenesis. Alternatively, since OTS-8 is involved
in cellular transformation [7], CD44^OTS-8 associa-
tion may cooperate to accelerate the proliferation of
sprouting TEC. Further investigation of CD44^OTS-
8 association on TEC might shed a new light on the
multiple functions of CD44 and an avenue toward
characterization of OTS-8 protein.
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